Literature DB >> 20378572

Paroxysmal nocturnal hemoglobinuria and eculizumab.

Lucio Luzzatto, Antonio Maria Risitano, Rosario Notaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20378572      PMCID： PMC2857178          DOI： 10.3324/haematol.2009.017848

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  30 in total

1.  STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT.

Authors:  T H Ham; J H Dingle
Journal:  J Clin Invest       Date:  1939-11       Impact factor: 14.808

Review 2.  Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease.

Authors:  J V Dacie; S M Lewis
Journal:  Ser Haematol       Date:  1972

3.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Authors:  Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

4.  Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody.

Authors:  W F Rosse; J V Dacie
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

5.  Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.

Authors:  Antonio M Risitano; Rosario Notaro; Ludovica Marando; Bianca Serio; Danilo Ranaldi; Elisa Seneca; Patrizia Ricci; Fiorella Alfinito; Andrea Camera; Giacomo Gianfaldoni; Angela Amendola; Carla Boschetti; Eros Di Bona; Giorgio Fratellanza; Filippo Barbano; Francesco Rodeghiero; Alberto Zanella; Anna Paola Iori; Carmine Selleri; Lucio Luzzatto; Bruno Rotoli
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

6.  Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.

Authors:  Jun-Ichi Nishimura; Yuzuru Kanakura; Russell E Ware; Tsutomu Shichishima; Hideki Nakakuma; Haruhiko Ninomiya; Carlos M Decastro; Sharon Hall; Akihisa Kanamaru; Keith M Sullivan; Hideaki Mizoguchi; Mitsuhiro Omine; Taroh Kinoshita; Wendell F Rosse
Journal:  Medicine (Baltimore)       Date:  2004-05       Impact factor: 1.889

7.  Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories.

Authors:  Régis Peffault de Latour; Jean Yves Mary; Célia Salanoubat; Louis Terriou; Gabriel Etienne; Mohamad Mohty; Sophie Roth; Sophie de Guibert; Sebastien Maury; Jean Yves Cahn; Gerard Socié
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

8.  Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria.

Authors:  M F McMullin; P Hillmen; J Jackson; P Ganly; L Luzzatto
Journal:  J Intern Med       Date:  1994-01       Impact factor: 8.989

9.  Natural history of paroxysmal nocturnal hemoglobinuria.

Authors:  P Hillmen; S M Lewis; M Bessler; L Luzzatto; J V Dacie
Journal:  N Engl J Med       Date:  1995-11-09       Impact factor: 91.245

10.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113
View more
  23 in total

1.  Unmanipulated haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with paroxysmal nocturnal hemoglobinuria and secondary aplastic anemia.

Authors:  M Sarmiento; P A Ramírez
Journal:  Bone Marrow Transplant       Date:  2015-10-26       Impact factor: 5.483

Review 2.  Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.

Authors:  Tolulase Olutogun; Ilaria Cutini; Rosario Notaro; Lucio Luzzatto
Journal:  Blood Transfus       Date:  2015-02-02       Impact factor: 3.443

3.  Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test.

Authors:  B Höchsmann; R Leichtle; I von Zabern; S Kaiser; W A Flegel; H Schrezenmeier
Journal:  Vox Sang       Date:  2011-09-19       Impact factor: 2.144

Review 4.  Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

Review 5.  Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; Antonio M Risitano; John D Lambris
Journal:  Semin Hematol       Date:  2018-02-14       Impact factor: 3.851

Review 6.  Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.

Authors:  D C Mastellos; D Ricklin; E Hajishengallis; G Hajishengallis; J D Lambris
Journal:  Mol Oral Microbiol       Date:  2015-10-07       Impact factor: 3.563

Review 7.  Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; Despina Yancopoulou; Antonio Risitano; John D Lambris
Journal:  Expert Rev Hematol       Date:  2014-09-02       Impact factor: 2.929

8.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

Authors:  Antonio M Risitano; Daniel Ricklin; Yijun Huang; Edimara S Reis; Hui Chen; Patrizia Ricci; Zhuoer Lin; Caterina Pascariello; Maddalena Raia; Michela Sica; Luigi Del Vecchio; Fabrizio Pane; Florea Lupu; Rosario Notaro; Ranillo R G Resuello; Robert A DeAngelis; John D Lambris
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

9.  Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Tommaso Rondelli; Antonio M Risitano; Régis Peffault de Latour; Michela Sica; Benedetta Peruzzi; Patrizia Ricci; Wilma Barcellini; Anna Paola Iori; Carla Boschetti; Veronica Valle; Veronique Frémeaux-Bacchi; Maria De Angioletti; Gerard Socie; Lucio Luzzatto; Rosario Notaro
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

10.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.